Colorectal Adenoma, Colorectal Cancer, Colorectal Neoplasms
Conditions
Keywords
FIT, Bacterial gene marker, Colonoscopy
Brief summary
The investigators aim to evaluate and compare the diagnostic accuracy of FIT and the novel panel of bacterial gene markers (Fn, m3, Ch and Bc) collectively named as M3, in detecting colorectal advanced neoplasia.
Detailed description
Colorectal cancer (CRC) is the one of the most common cancers in Hong Kong with more than 5,500 new cases annually. There is prevailing evidence of increasing trend of young onset CRC globally. Early detection and resection of pre-malignant colorectal neoplasia has shown to reduce CRC-related mortality. Non-invasive stool tests including guaiac-based faecal occult blood tests (gFOBT) and faecal immunochemical tests (FIT) are the cornerstones of population-based CRC screening programmes. The major limitation of this widely used strategy is its unsatisfactory sensitivities for CRC (79%) and advanced adenomas (AA; 40%). The sensitivity for non-advanced adenomas is even lower than 10%. A large proportion of advanced and non-advanced adenomas will be missed by FIT alone. Therefore, identification of alternative non-invasive test with better sensitivity to detect colorectal neoplasia is warranted. Multitarget stool DNA test and faecal microbial DNA markers appear to be promising options for CRC screening. Several bacterial gene markers have been identified by metagenome sequencing and reported to be associated with CRC, including Fusobacterium nucleatum (Fn), Clostridium hathewayi (Ch) and Bacteroides clarus (Bc). However, these molecular markers had low accuracy in distinguishing adenomas from normal tissue. Recently, a new Lachnoclostridium gene marker (labelled as 'm3') has been shown to have high diagnostic yield for the detection of colorectal adenomas. In a case-control study of 1012 subjects, a linear increasing trend of m3 level was observed from fecal samples of healthy subjects to those with adenomas and cancers. The overall sensitivity of m3 was significantly higher than FIT in detecting all adenomas (48% vs 9.3%), AA (50.8% vs 16.1%) and non-advanced adenomas (44.2% vs 0%). The diagnostic accuracy of m3 could be further enhanced by combining with a panel of fecal microbial markers composing of Fusobacterium nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi (Ch) for CRC (82.3%) and adenomas (64.2%). We hypothesized that the combination of these 4 bacterial gene markers (known as M3) is more sensitive than FIT in detecting colorectal advanced neoplasia.
Interventions
DIAGNOSTIC_TESTFecal immunochemical test (FIT)
A kind of stool test
Sponsors
Dr Cipto Mangunkusumo General Hospital
Aster CMI Hospital
Osaka International Cancer Institute
Sano hospital
Thingangyun Sanpya General Hospital
Changi General Hospital
National Taiwan University Hospital
Phramongkutklao College of Medicine and Hospital
St. Mark's Hospital
Oxford University Hospitals NHS Trust
Chinese University of Hong Kong
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. They require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms (e.g. anemia, change of bowel habit, abdominal pain); 2. Aged ≥18 years old; 3. Written informed consent obtained.
Exclusion criteria
1. Contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status); 2. Contraindication to polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets); 3. Known colorectal cancer or adenoma for staged procedure; 4. Previous colonic resection; 5. Personal history of colorectal cancer; 6. Personal history of polyposis syndrome; 7. Personal history of inflammatory bowel disease; 8. Known pregnancy or lactation; 9. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of bacterial gene markers panel (M3) | 1 month | The proportion of subjects with true positive results of M3 among those with one of more advanced neoplasia detected in the index colonoscopy. |
| Sensitivity of FIT/FOBT | 1 month | The proportion of subjects with true positive results of FIT among those with one of more advanced neoplasia detected in the index colonoscopy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of FIT/FOBT for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers | 1 month | The proportion of subjects with true positive results of FIT among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy. |
| Sensitivity of FIT/FOBT for advanced adenomas | 1 month | The proportion of subjects with true positive results of FIT among those with one or more advanced adenomas detected in the index colonoscopy. |
| Microbiota changes in subjects with adenomas or normal findings after polypectomy | 1 month | Microbiota change measured by qPCR or metagenomic sequencing |
| Sensitivity of M3 for advanced adenomas | 1 month | The proportion of subjects with true positive results of M3 among those with one or more advanced adenomas detected in the index colonoscopy. |
| Sensitivity of FIT/FOBT for all adenomas | 1 month | The proportion of subjects with true positive results of FIT among those with all advanced adenomas detected in the index colonoscopy. |
| Overall diagnostic accuracy | 1 month | The proportion of correctly classified subjects among all subjects |
| Sensitivity of FIT/FOBT for sessile serrated lesions (SSL) | 1 month | The proportion of subjects with true positive results of FIT among those with SSLs detected in the index colonoscopy. |
| Sensitivity of M3 for sessile serrated lesions (SSL) | 1 month | The proportion of subjects with true positive results of M3 among those with SSLs detected in the index colonoscopy. |
| Specificity | 1 month | The proportion of true negative results of M3/FOBT/FIT among those with no adenoma detected in colonoscopy |
| Positive predictive value (PPV) | 1 month | The ratio of subjects truly diagnosed as positive to all those who had positive test results |
| Negative predictive value (NPV) | 1 month | The ratio of subjects truly diagnosed as negative to all those who had negative test results |
| Sensitivity of M3 for all adenomas | 1 month | The proportion of subjects with true positive results of M3 among those with all advanced adenomas detected in the index colonoscopy. |
| Sensitivity of M3 for early-stage (stage 1) or invasive (stage 2-4) colorectal cancers | 1 month | The proportion of subjects with true positive results of M3 among those with early-stage (stage 1) or invasive (stage 2-4) colorectal cancers detected in the index colonoscopy. |
Countries
Hong Kong
Contacts
Primary ContactConnie Seto
Backup ContactMin Dai
Outcome results
None listed